



HAL
open science

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination

S. Lambert-Niclot, C. Allavena, M. Grude, P. Flandre, S. Sayon, E. André, M. Wirden, A. Rodallec, T. Jovelin, C. Katlama, et al.

► To cite this version:

S. Lambert-Niclot, C. Allavena, M. Grude, P. Flandre, S. Sayon, et al.. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. *Journal of Antimicrobial Chemotherapy*, 2016, 10.1093/jac/dkw146 . hal-01332106

HAL Id: hal-01332106

<https://hal.sorbonne-universite.fr/hal-01332106v1>

Submitted on 15 Jun 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Usefulness of an HIV DNA Resistance Genotypic Test in Patients Who Are Candidates
2 for a Switch to the rilpivirine/emtricitabine/tenofovir Combination

3
4 S Lambert-Niclot^{1*}, C Allavena², M Grude¹, P Flandre¹, S Sayon¹, E Andre³, M Wirden¹, A
5 Rodallec³, T Jovelin², C Katlama⁴, V Calvez¹, F Raffi², AG Marcelin¹.

6
7 1 Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, UMR_S 1136, Institut Pierre
8 Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Service de
9 Virologie, Paris, F-75013, France

10 2 Infectious Diseases Department, University Hospital of Nantes, Nantes, France

11 3 Virology, University Hospital of Nantes, Nantes, France

12 4 Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis
13 d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Service de maladies
14 Infectieuses, Paris, F-75013, France

15
16 Keywords :antiretroviral resistance, DNA genotype, rilpivirine

17
18 Running title: Switch to the RPV/TDF/FTC and DNA genotype

19 *Corresponding author: Sidonie LAMBERT-NICLOT

20 Mailing address: Department of Virology
21 Pitié-Salpêtrière Hospital
22 83 Boulevard de l'Hôpital, 75013 Paris, France

23 Phone: 33142177401, Fax: 33142177411

24 Email: sidonie.lambert@psl.aphp.fr

25
26 Abstract

27 **BACKGROUND:** In the context of a rilpivirine/emtricitabine/tenofovir switch in HIV-1
28 infected patients with at least one year of virologic success, we determined whether proviral
29 DNA is an alternative to plasma HIV-RNA for resistance genotyping.

30 **METHODS:** Resistance associated mutations (RAM) in DNA after at least one year of virologic
31 success (viral load (VL) <50 copies/mL) were compared with those identified in the last
32 plasma RNA genotype available. Rilpivirine/emtricitabine/tenofovir RAM studied were:
33 K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C
34 and M230I/L in reverse transcriptase. We studied patients without virologic failure (VF) and
35 with ≥ 1 VF (two consecutive VL>50 copies/mL). Kappa's coefficient was used to measure
36 agreement between the DNA and RNA genotypes.

37 **RESULTS:** In patients without (n=130) and with VF (n=114), RNA and DNA showed resistance
38 to at least one drug of the rilpivirine/emtricitabine/tenofovir combination in 8% and 9% and
39 in 60% and 45%, respectively. For rilpivirine RAM, correlation between RNA and DNA was
40 higher in patients without VF than in patients with VF (kappa= 0.60 versus 0.19, p=0.026).
41 Overall, prevalence of RAM was lower in DNA than in RNA.

42 **CONCLUSION:** The incomplete information provided by DNA genotypic test is more notable
43 in patients with VF, suggesting that all resistance mutations associated with prior VF have
44 not been archived in the proviral DNA or decreased to a level below threshold of detection.
45 In the case where no historical plasma genotypic test is available, DNA testing might be
46 useful to rule out switching to rilpivirine/emtricitabine/tenofovir.

47

48

49

50

51 INTRODUCTION

52

53 The second generation NNRTI rilpivirine (RPV) formulated in a single tablet regimen (STR)
54 with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) was approved by the
55 European Medicines Agency and the US Food and Drug Administration as a once-daily oral
56 treatment for adults infected with HIV-1 without mutations associated with resistance to
57 TDF, FTC, or the NNRTI class, and harboring a viral load (VL) $\leq 100\ 000$ HIV-1 RNA copies/mL.
58 Current antiretroviral treatment guidelines recommend switching therapy in virologically
59 suppressed patients to improve adherence or tolerability or to allow for treatment
60 simplification¹⁻³. The SPIRIT study showed maintenance of virologic suppression at W48 for
61 89.3% of patients switching to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) from a
62 ritonavir-boosted protease inhibitor (PI/r)-based regimen, compared with those who
63 continued treatment with a PI/r regimen with a low risk of virologic failure (VF)⁴. A study
64 demonstrated switching from efavirenz (EFV/FTC/TDF to RPV/FTC/TDF) was safe and
65 effective for virologically suppressed HIV-infected patients with EFV intolerance⁵. Cohort
66 studies have also shown efficacy and tolerability of switching to RPV/FTC/TDF⁶. Thus

67 RPV/FTC/TDF is considered as an appropriate therapy for switch for simplification in
68 virologically suppressed HIV infected patient.

69 In this context, the use of previous plasma resistance genotypes was recommended to
70 determine the susceptibility to this combination ³ because of the possible presence of pre-
71 existing drug resistance mutations leading to VF. Studies have shown that resistance testing
72 performed on HIV DNA lacks sensitivity compared with accumulated drug resistances from
73 previous plasma genotypes.^{7,8} However in patients fully virologically suppressed, the
74 previous plasma genotypic test could be unavailable.

75 In the perspective of a switch to the combination RPV/TDF/FTC, the aim of this study was to
76 determine whether proviral DNA is a potential relevant alternative to HIV-RNA for resistance
77 genotyping in HIV-1 infected treated patients with at least one year of virologic suppression.

78

79 MATERIAL and METHODS

80 In 244 HIV-1 infected patients treated in 2 centers (Nantes University Hospital and Pitié-
81 Salpêtrière Hospital) with a prior available RNA resistance test, we retrospectively analyzed
82 HIV DNA resistance genotype generated in PBMC after at least one year of virologic success
83 (VL <50 copies/mL). Bulk sequences of the reverse transcriptase (RT) on RNA and DNA were
84 determined using the ANRS consensus technique primer sequences described at
85 <http://www.hivfrenchresistance.org>. We compared prevalence of HIV resistance mutations in
86 the DNA and RNA genotype generated from the last detectable VL. We studied 2 groups of
87 patients: 130 patients without previous VF (pre-therapeutic plasma genotype) and 114
88 patients with at least one previous VF (genotype on the more recent detectable VL)

89 regardless of the treatment they received (VF was defined as two consecutive VL>50
90 copies/mL).

91 RPV/TDF/FTC combination resistance mutations studied were defined according to the IAS
92 list (K65R, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and
93 M230I/L) in RT⁹. Resistance to RPV was defined according the ANRS
94 <http://www.hivfrenchresistance.org/>. Kappa's coefficient was used to measure agreement
95 between the DNA and RNA genotypes with values <0, 0.-0.2, 0.21-0.4, 0.41-0.6, 0.61-0.8, and
96 0.81-1.00 indicating no, very low, low, middle, high, and very high concordance,
97 respectively.

98 We studied factors associated to the correlation between DNA and RNA mutations: VL, CD4
99 number at the time of both genotypes, number of treatment lines, number of previous VF
100 and mean time between last plasma RNA genotype and proviral DNA genotype.

101

102 RESULTS

103 We collected 244 pairs of DNA and RNA sequences for the RT gene (130 for patients without
104 VF and 114 for patients with at least one VF). Characteristics of patients are presented in
105 table 1. The mean time between last plasma RNA genotype and proviral DNA genotype was
106 46 and 37 months for patients without VF and with ≥ 1 VF, respectively. There are significant
107 differences between the 2 groups for VL RNA ($p \leq 0.0001$), numbers of lines of treatment
108 ($p \leq 0.0001$) and time between RNA and DNA genotypes ($p = 0.0025$).

109 In patients without VF, the prevalence of studied resistance associated mutation (RAM) was
110 very low in both RNA and DNA RT sequences (Figure 1a), with resistance to at least one drug
111 of the RPV/FTC/FTC combination in 8.0% and 9.0%, respectively.

112 In patients with at least one prior VF, the prevalence of at least one RPV RAM was 24.6% and
113 18.4 % in RNA and DNA genotype, respectively. The most prevalent RPV RAMs were
114 Y181C/I/V (12.3%) and E138A/G/K/Q/R (7.8%) in RNA genotype; and in DNA,
115 E138A/G/K/Q/R (7.9%) and M230I/L (6.1%) (Figure1b). Resistance to FTC and TDF was
116 detected in 52.6% (M184V/I) and 0.9% (K65R) in RNA genotype and 37.7% (M184V/I) and
117 0.9% (K65R) in DNA genotype. Resistance to at least one drug of the RPV/FTC/FTC
118 combination was 60.0% in RNA and 45.0% in DNA.

119 In patients without VF, concordance between resistance in RNA and DNA was not
120 significantly higher than in patients with VF (kappa= 0.57 versus 0.43 respectively, $p=0.36$).

121 For RPV RAM, correlation between RNA and DNA was significantly higher in patients without
122 VF than in patients with at least one VF (kappa= 0.60 versus 0.19 respectively, $p=0.026$).

123 Overall, prevalence of rilpivirine associated mutations was lower in DNA than in RNA
124 genotypic test, except for mutations at positions E138 and M230 that are APOBEC driven
125 mutations (G to A) (Figure 1b). The factors associated with a good correlation between
126 resistance according RNA and DNA genotype were a higher VL at RNA genotype ($p=0.0124$),
127 a shorter mean time between last plasma RNA genotype and proviral DNA genotype
128 ($p=0.0468$) and a higher number of treatment lines ($p=0.0006$). Number of VF, subtypes, CD4
129 at the time of RNA genotype or DNA genotype were not associated with correlation of
130 resistance in RNA and DNA.

131

132 DISCUSSION

133 In the context of switch to RPV/TDF/FTC therapy in HIV-1 infected treated patients, this
134 study shows a good concordance between DNA and RNA genotypes in patients without prior
135 VF and who are successfully suppressed for at least one year. However, DNA genotype is less
136 informative than RNA genotype in patients with at least one prior VF. The good concordance
137 in patients with no prior VF is in accordance with results of studies on naive patients showing
138 that DNA genotype could be useful and even more informative than standard RNA
139 genotyping^{10,11} .

140 In patients with at least one prior VF, the rate of selected resistance associated mutations to
141 RPV in RNA was somewhat lower than in previous studies conducted in patients pre-exposed
142 to an NNRTI-based regimen but naive to RPV¹²⁻¹⁴ . Indeed, in our study the 3 main RPV
143 RAMs at codons 181, 101 and 138 had a frequency of 12.3, 2.6 and 5.3% versus 18 to 22.6%,
144 7 to 20.5% and 5.3 to 14% in these 3 studies, respectively. This lower frequency could be due
145 to the fact that our studied population not exclusively contained NNRTI failing patients,
146 nevertheless the 3 mains RPV RAM are similar to those observed in others studies. In the HIV
147 DNA, we showed a lower prevalence of the RPV RAM: 101, 181 and 221 with 0.9%, 3.5% and
148 0.9% versus 7%, 18% and 4% in the study of Gallien et al¹² . However, patients of this study
149 were selected to have a prior VF especially to NVP or EFV and had a prior history of triple
150 class failure.

151 In patients with prior VF, our study generally confirmed results of previous studies on the
152 discordance between DNA and RNA genotypes. Indeed, in a large number of patients with
153 undetectable or low VL under treatment, a study showed a concordance between DNA and
154 RNA of 26.3% for NNRTI mutations⁷. Another study demonstrated that mutations conferring

155 resistance to at least one antiretroviral drug were detected exclusively by RNA genotyping or
156 exclusively by DNA genotyping in 47% and 1% of patients for NNRTIs, respectively⁸.

157 Overall, prevalence of RAM was generally lower in DNA than in RNA genotypic tests, except
158 for mutations at positions E138 and M230 that are APOBEC driven mutations. Indeed,
159 APOBEC induces G to A viral mutation and this mechanism could explain the persistence of
160 mutations in archived cellular proviral DNA¹⁵.

161 The incomplete information provided by the DNA test is more notable in patients with at
162 least one prior VF, suggesting that all resistance mutations associated with the prior VF may
163 not have been archived in the proviral DNA or not detected with classical Sanger sequencing.
164 A good correlation between prior RNA genotype and current DNA genotype was significantly
165 associated with a higher VL at RNA genotype and a shorter mean time between last plasma
166 RNA and proviral DNA genotype. This suggest that DNA genotypic testing, with current
167 techniques, might be suboptimal in case of low intracellular VL of resistant viruses and that
168 archived resistant viruses might decrease over time. Further studies would be warranted to
169 explore the interest of Ultra Deep Sequencing on DNA and the clinical relevance of minority
170 variants.

171 From a clinical perspective, we recommend that before switching to RPV/TDF/FTC, one takes
172 into consideration full treatment history and available past plasma genotypic testing, and in
173 the absence of prior plasma genotype, avoid use of RPV/TDF/FTC if RAM to this combination
174 are detected using a DNA genotype in a virologically suppressed patient.

175

176 **Acknowledgements**

177 We thank G. Le Mallier and P. Grange for their technical assistance.

178 **Funding section**

179 This work was supported by the Agence Nationale de Recherches sur le SIDA (ANRS).

180 **Transparency declarations**

181 F. R. has received honoraria for advisories or invited talks or conferences and research grants
182 from Abbvie Labs, Bristol-Myers Squibb, Gilead Sciences, Merck Laboratories, MSD, Janssen
183 Pharmaceuticals and ViiV Healthcare. A. G. M. has received honoraria for advisories or
184 invited talks or conferences and research grants from Abbvie Labs, Bristol-Myers Squibb,
185 Gilead Sciences, Merck Laboratories, MSD, Janssen Pharmaceuticals and ViiV Healthcare. V.
186 C. has received honoraria for advisories or invited talks or conferences and research grants
187 from Abbvie Labs, Bristol-Myers Squibb, Gilead Sciences, Merck Laboratories, MSD, Janssen
188 Pharmaceuticals and ViiV Healthcare. The other authors have none to declare.

189

190

191 **REFERENCES**

192 1. Guidelines-7.1-english.pdf. Available at: [http://www.eacsociety.org/files/guidelines-7.1-](http://www.eacsociety.org/files/guidelines-7.1-english.pdf)
193 [english.pdf](http://www.eacsociety.org/files/guidelines-7.1-english.pdf).

194 2. HIV/AIDS Guidelines - adultandadolescentgl.pdf. Available at:
195 <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>.

196 3. Rapport_Morlat_2013_Mise_en_ligne.pdf. Available at:
197 http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf.

198 4. Palella FJ, Fisher M, Tebas P, *et al*. Simplification to rilpivirine/emtricitabine/tenofovir
199 disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a
200 randomized trial of HIV-1 RNA-suppressed participants. *AIDS Lond Engl* 2014; **28**: 335–44.

- 201 5. Mills AM, Cohen C, Dejesus E, *et al.* Efficacy and safety 48 weeks after switching from
202 efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet
203 regimens. *HIV Clin Trials* 2013; **14**: 216–23.
- 204 6. Cazanave C, Reigadas S, Mazubert C, *et al.* Switch to Rilpivirine/Emtricitabine/Tenofovir
205 Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients,
206 Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort,
207 2012–2014. *Open Forum Infect Dis* 2015
- 208 7. Wirlden M, Soulie C, Valantin M-A, *et al.* Historical HIV-RNA resistance test results are
209 more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
210 *J Antimicrob Chemother* 2011; **66**: 709–12.
- 211 8. Delaugerre C, Braun J, Charreau I, *et al.* Comparison of resistance mutation patterns in
212 historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes
213 among extensively treated patients with suppressed replication. *HIV Med* 2012; **13**: 517–25.
- 214 9. Complera_pi.pdf. Available at:
215 http://www.gilead.com/~media/files/pdfs/medicines/hiv/complera/complera_pi.pdf?la=en
- 216 10. Ellis GM, Page LC, Burman BE, Buskin S, Frenkel LM. Increased detection of HIV-1 drug
217 resistance at time of diagnosis by testing viral DNA with a sensitive assay. *J Acquir Immune*
218 *Defic Syndr* 1999 2009; **51**: 283–9.
- 219 11. Kabamba-Mukadi B, Duquenne A, Henrivaux P, *et al.* HIV-1 proviral resistance mutations:
220 usefulness in clinical practice. *HIV Med* 2010; **11**: 483–92.
- 221 12. Gallien S, Charreau I, Nere ML, *et al.* Archived HIV-1 DNA resistance mutations to
222 rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to
223 efavirenz or nevirapine. *J Antimicrob Chemother* 2015; **70**: 562–5.
- 224 13. Anta L, Llibre JM, Poveda E, *et al.* Rilpivirine resistance mutations in HIV patients failing
225 non-nucleoside reverse transcriptase inhibitor-based therapies. *AIDS Lond Engl* 2013; **27**:
226 81–5.
- 227 14. Lambert-Niclot S, Charpentier C, Storto A, *et al.* Rilpivirine, emtricitabine and tenofovir
228 resistance in HIV-1-infected rilpivirine-naïve patients failing antiretroviral therapy. *J*
229 *Antimicrob Chemother* 2014; **69**: 1086–9.
- 230 15. Mulder LCF, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. *Proc*
231 *Natl Acad Sci U S A* 2008; **105**: 5501–6.

232

233

234

235 **Table 1:** Characteristics of patients according the 2 groups: without previous virologic failure
 236 (VF) and patients with ≥ 1 VF. *corresponding to pretreatment VL for patients without
 237 previous VF and VL at failure for patients with at least one VF


	Without VF N=130 Median (standard deviation)	With at least one VF N=114 Median (standard deviation)
VL RNA log copies/mL*	4.5 (1.2)	3.0 (1.1)
CD4 at time of RNA genotype Number of cells/mm3	347 (230.2)	358 (251.6)
CD4 at time of DNA genotype Number of cells/mm3	586 (311.6)	537 (338.2)
Time between RNA and DNA genotypes (month)	43 (31)	29.5 (36.8)
Number of lines of treatment	3 (3.3)	12 (7.5)

238

239

240 Figure 1 : Prevalence of resistance mutations to RPV/TDF/FTC in RNA and in DNA : a) in patients
 241 without previous virologic failure. b) in patients with at least one virologic failure.* correspond to
 242 statistical significant difference of prevalence of resistance mutations between DNA and RNA
 243 ($p < 0.05$)

244 a)




245

246

247

248

249 b)



250